Type: Oral
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond
Hematology Disease Topics & Pathways:
Combination therapy, Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Diseases, Immunotherapy, Biological therapies, Treatment Considerations, Lymphoid Malignancies
Methods: Eligible pts had RRMM with documented progressive disease (PD) during or after the last regimen, ECOG performance status score ≤1, and were intolerant to or ineligible for all available established therapies. Oral MEZI was given daily (QD) at escalating doses of 0.3, 0.6, or 1.0 mg on days (D)1–21 of each 28-D cycle with 40 mg (20 mg if ≥75 y of age) weekly DEX plus 800 mg twice daily oral TAZ on D1–28; 2 or 3 mg QD oral BMS-986158 5D-on-2D-off D1–14; or 1.5 or 2 mg QD oral TRAM on D1–21. Primary objectives included defining the recommended phase 2 dose and dosing schedule, and evaluating safety. Secondary objectives included efficacy and pharmacokinetics. There was no biomarker screening.
Results: As of May 8, 2024, 14 pts received MEZId + TAZ, 16 MEZId + BMS-986158, and 15 MEZId + TRAM. Across all cohorts, median (range) age was 63 (37–83) y and median time since initial diagnosis was 7.5 (2.0–18.4) y. Eight (18%) pts were Black/African American, 35 (78%) White, and race was not collected/unknown (NA) in 2 (4%); 6 (13%) were Hispanic/Latino and 36 (80%) were not (NA = 3 [7%] pts); 56% were in the United States. Extramedullary plasmacytomas were present in 16 (36%) pts. The median number of prior antimyeloma regimens was 5 (2–20). Prior therapies included autologous stem cell transplantation (78%), IMiD agents (100%), proteasome inhibitors (PIs; 100%), anti-CD38 monoclonal antibodies (mAbs; 100%), and T cell-redirecting therapy (58%); 82% had triple-class refractory disease (to an IMiD agent, PI, and anti-CD38 mAb).
At data cutoff, 7 (50%) pts continued on treatment in the MEZId + TAZ cohort, 8 (50%) in the MEZId + BMS-986158 cohort, and 10 (67%) in the MEZId + TRAM cohort. The main reason for discontinuation in all 3 cohorts was PD. Median follow-up was 4.1 (1.0–11.0) mo (MEZId + TAZ), 2.9 (1.0–6.5) mo (MEZId + BMS-986158), and 3.6 (0–10.6) mo (MEZId + TRAM).
The most frequent grade (Gr) 3/4 treatment-emergent adverse event (TEAE) across all 3 cohorts was neutropenia (43–73%); Gr 3/4 non-hematologic TEAEs were low or absent. Three pts had dose-limiting toxicities (1 with 0.3 mg MEZId + BMS-986158, 1 with 1.0 mg MEZId + BMS-986158, and 1 with 1.0 mg MEZId + TRAM).
In the efficacy-evaluable population, overall response rate (≥ partial response [PR]) was 54% (7/13 pts) with MEZId + TAZ; 36% (5/14) with MEZId + BMS-986158; and 92% (11/12) with MEZId + TRAM. In the MEZId + TAZ and MEZId + BMS-986158 cohorts, deeper responses (≥ very good PR), including 1 stringent complete response (sCR) with MEZId + TAZ, were observed with 1.0 mg MEZI, and in the MEZId + TRAM cohort with ≥0.6 mg MEZI (including 1 sCR), and 100% (5/5 pts) at 1.0 mg MEZI were ongoing responses with this combination.
Exposures increased in a dose-linear manner over the dose range and were consistent across treatment cohorts, demonstrating no drug-drug interaction between MEZI and novel therapeutic agents. MEZI remained pharmacodynamically active, inducing Ikaros/Aiolos degradation and B-cell reduction with all combination agents at all dose levels, with the greatest effect observed at MEZI 1.0 mg.
Conclusions: MEZId combined with the novel therapeutic agents TAZ, BMS-986158, or TRAM showed promising efficacy and a manageable safety profile in patients with RRMM. No new safety signals were identified, with neutropenia being the most common Gr 3/4 TEAE in all 3 cohorts. These results provide a rationale for further exploration of these novel all-oral combinations. Accrual continues and updated results will be presented at the meeting.
Disclosures: Costa: Janssen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Caribou: Research Funding; Genentech, Inc.: Consultancy, Honoraria, Research Funding; Adaptive biotechnoligies: Honoraria; Pfizer: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria. Schjesvold: Takeda: Consultancy, Other: Honoraria for lectures and educational material; Amgen: Other: Honoraria for lectures and educational material; Targovax: Research Funding; Celgene: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; AbbVie: Consultancy, Other: Honoraria for lectures and educational material; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Other: Honoraria for lectures and educational material; GSK: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; SkylineDx: Other: Honoraria for lectures and educational material; Novartis: Other: Honoraria for lectures and educational material; Daiichi Sankyo: Other: Honoraria for lectures and educational material; Janssen-Cilag: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Oncopeptides: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Pfizer: Other: Honoraria for lectures and educational material; Schain: Other: Honoraria for lectures and educational material; Skylite: Other: Honoraria for lectures and educational material. Popat: Pfizer: Honoraria, Research Funding, Speakers Bureau; GSK: Honoraria, Research Funding; Sanofi: Honoraria; Janssen: Honoraria, Speakers Bureau; Abbvie: Honoraria; BMS: Honoraria. Usmani: Bristol-Myers Squibb: Consultancy, Research Funding; Array Biopharma: Research Funding; Gracell: Consultancy; Abbvie: Consultancy, Research Funding; SkylineDX: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Pharmacyclics: Research Funding; SeaGen: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; SecuraBio: Consultancy; Gilead: Research Funding; Oncopeptides: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy, Research Funding; Bristol-Myers Squibb - Celgene:: Consultancy, Research Funding; EdoPharma: Consultancy; Takeda: Consultancy, Research Funding; TeneoBio: Consultancy; GSK: Consultancy, Research Funding; Merck: Research Funding; Genentech: Consultancy; Bristol-Myers Squibb - Celgene: Consultancy, Research Funding; Johnson & Johnson - Janssen: Consultancy, Research Funding. Ali: Bristol Myers Squibb: Consultancy, Research Funding; Pfizer/IMF: Research Funding; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees. Chu: Pfizer: Honoraria; Janssen: Honoraria; AstraZeneca: Honoraria; Amgen: Honoraria; Kite/Gilead: Honoraria; Sanofi: Honoraria; Amgen: Consultancy; BMS: Honoraria. Hartley-Brown: Sanofi: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria, Research Funding; Multiple Myeloma Research Foundation: Consultancy, Honoraria, Research Funding; Cancer Care: Consultancy, Honoraria. Bahlis: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, Kyte, Novartis, Pfizer, Roche, Sanofi, Takeda: Consultancy; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Genentech, Karyopharm Therapeutics, Kyte, Novartis, Pfizer, Roche, Sanofi, Takeda: Membership on an entity's Board of Directors or advisory committees; Janssen, Pfizer: Research Funding; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Genentech, Karyopharm Therapeutics, Kyte, Novartis, Pfizer, Roche, Sanofi, Takeda: Honoraria. Oriol: Sanofi: Honoraria, Speakers Bureau; Pfizer, Amgen, Oncopeptides: Honoraria; GSK: Honoraria, Speakers Bureau; Bristol Myers Squibb/Celgene: Honoraria, Speakers Bureau; Johnson & Johnson, Janssen: Honoraria, Speakers Bureau. Lopez: BMS, Pfizer, Janssen, Amgen, Roche, Kite: Consultancy; BMS, Pfizer, Janssen, Amgen, Roche, Kite: Honoraria; Pfizer, Janssen, Incity: Research Funding. Ocio: Takeda: Consultancy, Honoraria; Regeneron: Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria, Research Funding; Menarini: Consultancy, Honoraria; AstraZeneca: Consultancy; Janssen: Consultancy, Honoraria, Speakers Bureau; Amgen: Honoraria; GSK: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria. Ramasamy: Bristol-Myers Squibb: Other: Travel; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Recordati: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Menarini: Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees; Johnson & Johnson - Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb - Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding. Reece: Janssen, BMS, Sanofi, ORIC, Princess Margaret Cancer Centre: Other: Grants; BMS, Janssen, Sanofi, GSK, Pfizer: Consultancy; BMS, Janssen, Takeda, Pfizer: Honoraria; BMS: Membership on an entity's Board of Directors or advisory committees. Searle: DarkBlue Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Jazz: Speakers Bureau; AbbVie: Honoraria, Speakers Bureau; Beigene: Honoraria; Nurix: Honoraria. Gaudy: BMS: Current Employment, Current equity holder in publicly-traded company. Kurtova: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Zhang: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Sarmiento: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Dietrich: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Katz: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Pourdehnad: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Richardson: Oncopeptides: Research Funding; Celgene/Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron, Sanofi: Consultancy.